The final analysis of the phase 3 Targeted Investigational Treatment Analysis of Novel Anti-androgen(TITAN)trial showed improvement in overall survival(OS)and other efficacy endpoints with apalutamide plus androgen de...
详细信息
The final analysis of the phase 3 Targeted Investigational Treatment Analysis of Novel Anti-androgen(TITAN)trial showed improvement in overall survival(OS)and other efficacy endpoints with apalutamide plus androgen deprivation therapy(ADT)versus ADT alone in patients with metastatic castration-sensitive prostate cancer(mCSPC).As ethnicity and regional differences may affect treatment outcomes in advanced prostate cancer,a post hoc final analysis was conducted to assess the efficacy and safety of apalutamide in the Asian ***-driven endpoints were OS,and time from randomization to initiation of castration resistance,prostate-specific antigen(PSA)progression,and second progression-free survival(PFS2)on first subsequent therapy or *** endpoints were assessed using the Kaplan–Meier method and Cox proportional-hazards models without formal statistical testing and adjustment for *** Asian patients received once-daily apalutamide 240 mg(n=111)or placebo(n=110)plus *** a median follow-up of 42.5 months and despite crossover of 47 placebo recipients to open-label apalutamide,apalutamide reduced the risk of death by 32%(hazard ratio[HR]:0.68;95%confidence interval[CI]:0.42–1.13),risk of castration resistance by 69%(HR:0.31;95%CI:0.21–0.46),PSA progression by 79%(HR:0.21;95%CI:0.13–0.35)and PFS2 by 24%(HR:0.76;95%CI:0.44–1.29)relative to *** outcomes were comparable between subgroups with low-and high-volume disease at *** new safety issues were *** provides valuable clinical benefits to Asian patients with mCSPC,with an efficacy and safety profile consistent with that in the overall patient population.
BACKGROUND Multiple genetic risk factors for Crohn’s disease(CD)have been ***,these observations are not consistent across different *** protein tyrosine phosphate non-receptor type 2(PTPN2)gene plays a role in vario...
详细信息
BACKGROUND Multiple genetic risk factors for Crohn’s disease(CD)have been ***,these observations are not consistent across different *** protein tyrosine phosphate non-receptor type 2(PTPN2)gene plays a role in various aspects of host defense including epithelial barrier function,autophagy,and innate and adaptive immune *** common polymorphisms in the PTPN2 gene(rs2542151 and rs7234029)have been associated with risk of CD in Western *** To evaluate the association of PTPN2 gene polymorphisms with risk of CD in Indian *** We conducted a prospective case-control *** with CD were recruited,and their clinical and investigation details were *** were patients without organic gastrointestinal disease or other comorbid *** common polymorphisms in the PTPN2 gene(rs2542151 and rs7234029)were *** was extracted from peripheral blood samples of cases and controls and target DNA was amplified using specific sets of *** amplified fragments were digested with restriction enzymes and the presence of polymorphism was detected by restriction fragment length *** frequency of alleles was *** frequencies of genotypes and alleles were compared between cases and controls to look for significant *** A total of 108 patients with CD(mean age 37.5±12.7 years,females 42.6%)and 100 controls(mean age 39.9±13.5 years,females 37%)were *** the single nucleotide polymorphism(SNP)rs7234029,the overall frequency of G variant genotype(AG or GG)was noted to be significantly lower in the cases compared to controls(35.2%vs 50%,P=0.05).For the SNP rs2542151,the overall frequency of G variant genotype(GT or GG)was noted to be similar in cases compared to controls(43.6%vs 47%,P=0.73).There were no significant differences in minor allele(G)frequency for both polymorphisms between the cases and *** the SNPs had no significant association with a
暂无评论